34 completed, 9 terminated, 5 recruiting, 5 withdrawn. 59 Phase 2, 11 Phase 1, 3 Phase 3.
Follow Panuveitis: new trials by email Literature Review of Panuveitis trials Research Report on Panuveitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial Of Tulisokibart In Participants With Active, Non-Infectious Uveitis (MK-7240-019) Tulisokibart, Placebo, Background prednisone therapy - Noninfectious Intermediate, Posterior, or Panuveitis | Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 87 | 2026-11-04 | 2026-11-09 |
| Systemic and Topical Antiviral Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes - Trials I and II Valganciclovir, Ganciclovir (GCV), Placebo - Cytomegalovirus (CMV), Anterior Uveitis | Phase 2 | Not yet recruiting | University of California, San Francisco | 117 | 2026-11-01 | 2026-08-11 |
| Corticotropin for Behçet's Disease: A Multicenter Randomized Controlled TrialAcronym. Repository Corticotropin Injection (ACTH), Study-matched inactive placebo injection, also called control injection - Behçet's Syndrome, Behçet's Syndrome (BS) | Phase 2 | Not yet recruiting | Peking University People's Hospital | 60 | 2026-09-01 | 2026-09-22 |
| Ivarmacitinib for Refractory Behcet's Syndrome Ivarmacitinib - Behcet's Syndrome | Phase 2 | Withdrawn | Liu Tian | 2026-06-01 | 2026-07-10 | |
| A Study of REGN7041 for Active Noninfectious Uveitis in Adult Participants REGN7041 - Active Noninfectious Uveitis Affecting the Posterior Segment | Phase 1 / Phase 2 | Terminated | Regeneron Pharmaceuticals | 1 | 2025-12-17 | 2026-08-17 |
| BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases BCMA-CD19 CAR-T therapy - Systemic Lupus Erythematosus, Inflammatory Myopathy | Phase 2 | Recruiting | Peking University People's Hospital | 50 | 2024-12-26 | 2025-04-02 |
| Dusquetide for the Treatment of Behcet's Disease Dusquetide - Behçet Disease | Phase 2 | Completed | Soligenix | 8 | 2024-11-18 | 2026-08-26 |
| Baricitinib in the Treatment of Intestinal Behçet's Syndrome Baricitinib, Adalimumab - Behcet Syndrome, Intestinal Type | Phase 2 | Recruiting | Peking Union Medical College Hospital | 56 | 2024-11-08 | 2026-09-21 |
| Ustekinumab for Intestinal Behçet's Syndrome With Myelodysplastic Syndrome Ustekinumab 90 mg - Behcet's Syndrome, Intestinal Type, Myelodysplastic Syndrome | Phase 2 | Completed | Liu Tian | 8 | 2024-03-24 | 2026-05-13 |
| Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases Filgotinib - Behcet's Disease, Idiopathic Inflammatory Myopathies | Phase 2 | Recruiting | UMC Utrecht | 60 | 2024-03-12 | 2026-05-12 |
| Topical Pentoxifylline Gel on Behcet's Disease Genital Ulcers Topical Pentoxifylline Gel (Vehicle +PTX), Topical Placebo Gel (Vehicle) - Behcet Syndrome, Behcet Disease | Phase 2 | Unknown | Silk Road Therapies, Inc. | 60 | 2024-02-01 | 2023-08-03 |
| Upadacitinib for Refractory Behcet's Syndrome Upadacitinib 15 MG - Behcet Syndrome | Phase 2 | Completed | Liu Tian | 27 | 2024-01-25 | 2025-12-02 |
| A Phase 2 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis VVN461 Ophthalmic Solution 1.0%, VVN461 Ophthalmic Solution 0.5%, Prednisolone acetate - Anterior Uveitis | Phase 2 | Completed | VivaVision Biotech, Inc | 89 | 2023-11-27 | 2025-01-27 |
| Tocilizumab and Tofacitinib in the Treatment of Vascular Behçet's Syndrome tocilizumab, tofacitinib, cyclophosphamide - Aneurysm, Behcet Syndrome, Vascular Type | Phase 2 | Recruiting | Peking Union Medical College Hospital | 81 | 2023-06-01 | 2024-08-19 |
| Intravitreal Sirolimus as Therapeutic Approach to Uveitis Intravitreal injection 440mcg, Intravitreal injection of sirolimus 880mcg - Uveitis, Intermediate Uveitis | Phase 2 | Withdrawn | Stanford University | 2022-09-01 | 2023-10-26 | |
| Phase 2b Pivotal Study of Izokibep in Non-infectious, Intermediate-, Posterior- or Pan-uveitis Izokibep, Placebo - Uveitis | Phase 2 | Terminated | ACELYRIN Inc. | 96 | 2022-08-23 | 2025-02-21 |
| Results of Suprachoroidal Steroids Injections in Two Chorioretinal Diseases Triamcinolone Acetonide - Central Serous Chorioretinopathy, Irvine-Gass Syndrome | Phase 2 / Phase 3 | Unknown | Benha University | 50 | 2022-04-14 | 2022-04-20 |
| Low-dose IL-2 Treatment on Behcet's Disease Low-dose IL-2, Placebo - Behcet's Disease | Phase 2 | Completed | HeJing | 60 | 2021-10-12 | 2024-04-03 |
| A Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet Disease Hemay005, Placebo - Behçet Disease | Phase 2 | Terminated | Tianjin Hemay Pharmaceutical Co., Ltd | 89 | 2020-11-30 | 2022-06-21 |
| Golimumab for the Treatment of Refractory Behcet's Uveitis Golimumab (GOL) - Behcet Syndrome, Uveitis | Phase 2 | Terminated | Wenjie Zheng | 1 | 2020-02-15 | 2023-04-07 |
Showing 20 of 59. Sign in to see all of them.
Behcet Syndrome (28) · Uveitis (24) · Uveitis, Posterior (16) · Uveitis, Anterior (13) · Uveitis, Intermediate (13) · Macular Edema (7) · Inflammation (3) · Retinal Vasculitis (3) · Birdshot Chorioretinopathy (2) · Choroidal Effusions (2) · Immunoglobulin G4-Related Disease (2) · Lupus Erythematosus, Systemic (2) · Myositis (2) · Ophthalmia, Sympathetic (2)
Eye Diseases (59) · Uveal Diseases (59) · Uveitis (35) · Cardiovascular Diseases (30) · Skin and Connective Tissue Diseases (30) · Vascular Diseases (30) · Skin Diseases (29) · Skin Diseases, Vascular (29) · Vasculitis (29) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (28) · Genetic Diseases, Inborn (28) · Hereditary Autoinflammatory Diseases (28) · Mouth Diseases (28) · Skin Diseases, Genetic (28)
tocilizumab (4) · Daclizumab (3) · Dexamethasone (3) · prednisolone acetate (3) · Adrenocorticotropic Hormone (2) · Cyclophosphamide (2) · Interleukin-2 (2) · Methotrexate (2) · Ophthalmic Solutions (2) · Triamcinolone Acetonide (2) · Ustekinumab (2) · Adalimumab (1) · Adrenal Cortex Hormones (1) · CF101 (1) · Colchicine (1)
National Eye Institute (NEI) (6) · Allergan (3) · Assistance Publique - Hôpitaux de Paris (3) · Liu Tian (3) · Novartis Pharmaceuticals (3) · Clearside Biomedical, Inc. (2) · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (2) · Peking Union Medical College Hospital (2) · Peking University People's Hospital (2) · Tehran University of Medical Sciences (2) · Wenjie Zheng (2) · ACELYRIN Inc. (1) · Aciont Inc (1) · Alcon Research (1) · Aldeyra Therapeutics, Inc. (1)
United States (30) · China (12) · France (5) · Germany (4) · Turkey (Türkiye) (4) · United Kingdom (3) · Austria (2) · Czechia (2) · India (2) · Iran (2) · Israel (2) · Spain (2) · Australia (1) · Brazil (1) · Canada (1)
Bahar Sadeghi, MD (2) · Hatice N Sen, M.D. (2) · Quan D Nguyen, MD, MSc (2) · Thomas Ciulla, MD (2) · Wenjie Zheng, M.D. (2) · Ahmed A Abdelshafy, MD (1) · Ahmet Gul, MD (1) · Andew J Sulich, MD (1) · Arash Tehrani Banihashemi, MD, MPH (1) · Ayhan Dinc, MD (1)
PMID 15079763, PMID 17353400, PMID 19268890, PMID 19597921, PMID 19664754, PMID 1970380, PMID 19717547, PMID 20212194, PMID 20212197, PMID 20704622, PMID 20926833, PMID 21220619, PMID 23411886, PMID 23761087, PMID 25638011, PMID 25875256, PMID 27980877, PMID 28335798, PMID 28528519, PMID 29471416, PMID 30472651, PMID 32955967, PMID 33042579, PMID 34864108, PMID 37172782, PMID 37316690, PMID 38782788, PMID 39915014, PMID 41400947, PMID 41748391
2025 (2), R44EY014772 (1), UG1EY036344 (1)